Braintree Beats Colon-Cleanser Patent Invalidity Claims

Law360, New York (June 5, 2013, 1:32 PM EDT) -- A New Jersey federal judge said Tuesday that Braintree Laboratories Inc.'s patent on Suprep is valid, a ruling that follows the judge's finding in January that Novel Laboratories Inc.'s plan to make a generic version of the colon cleanser infringed the patent.

U.S. District Judge Peter G. Sheridan struck down various arguments that Braintree's U.S. Patent Number 6,946,149 was invalid, finding that Novel had not presented convincing enough evidence to back its invalidity claims. The '149 patent covers Braintree's Suprep, a laxative formula used to clear...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.